SUPNSupernus Pharmaceuticals, Inc.

SUPN Stock Price, Valuation & Chart | Supernus Pharmaceuticals, Inc.

$44.030+0.29 (+0.66%)

At close · 02 Sept 2026, 08:00 pm

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic SUPN intrinsic value SUPN calculated fair value vs price

Overview Financials Dividends Ratios

SUPN Historical price chart

SUPN Key Stats

Fair Value

Disclaimer

Disclaimer: This fair value estimate is for informational purposes only and should not be considered as investment advice. Fair value calculations are based on DCF (Discounted Cash Flow), P/E Multiple, and P/S Multiple models and assumptions that may not reflect actual market conditions. Always conduct your own research and consult with a financial advisor before making investment decisions.

Unlock

Market Capitalization2.56B

PE Ratio14.39

EPS3.06

Trading Volume445.94K

Today's High/Low45.05/43.67

Dividend Yield0.00

52 Week High/Low59.68/42.45

Shares Outstanding58.04M

SUPN Financial Statement

SUPN Analyst ratings

SUPN Analysis & performance metrics

SUPN Company profile

Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS)…

Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar…

SUPN Management team

Name

Position

Frank Mottola

Senior Vice President of Quality, GMP Operations, Information Technology and Regulatory Affairs

Taylor Raiford

Senior Vice President of Sales

Kevin T. Anderson Esq.

Compliance Officer

Jack A. Khattar M.B.A.CEO

Founder, President, Chief Executive Officer, Secretary & Director

Todd Horich M.B.A., Ph.D.

Senior Vice President of Marketing, Commercial Operations & Market Access

Jeff Bozick

Senior Vice President of Supply Chain

Jonathan Rubin M.B.A., M.D.

Senior Vice President of Research & Development and Chief Medical Officer

Bryan A. Roecklein Ph.D.

Senior Vice President of Corporate Development

Name

Position

Frank Mottola

Senior Vice President of Quality, GMP Operations, Information Technology and Regulatory Affairs

Taylor Raiford

Senior Vice President of Sales

Kevin T. Anderson Esq.

Compliance Officer

Jack A. Khattar M.B.A.CEO

Founder, President, Chief Executive Officer, Secretary & Director

Todd Horich M.B.A., Ph.D.

Senior Vice President of Marketing, Commercial Operations & Market Access

Jeff Bozick

Senior Vice President of Supply Chain

Jonathan Rubin M.B.A., M.D.

Senior Vice President of Research & Development and Chief Medical Officer

Bryan A. Roecklein Ph.D.

Senior Vice President of Corporate Development

Management Team

Frank Mottola

Senior Vice President of Quality, GMP Operations, Information Technology and Regulatory Affairs

Taylor Raiford

Senior Vice President of Sales

Kevin T. Anderson Esq.

Compliance Officer

Jack A. Khattar M.B.A.CEO

Founder, President, Chief Executive Officer, Secretary & Director

Todd Horich M.B.A., Ph.D.

Senior Vice President of Marketing, Commercial Operations & Market Access

Jeff Bozick

Senior Vice President of Supply Chain

Jonathan Rubin M.B.A., M.D.

Senior Vice President of Research & Development and Chief Medical Officer

Bryan A. Roecklein Ph.D.

Senior Vice President of Corporate Development

Management

Frank Mottola

Senior Vice President of Quality, GMP Operations, Information Technology and Regulatory Affairs

Taylor Raiford

Senior Vice President of Sales

Kevin T. Anderson Esq.

Compliance Officer

Jack A. Khattar M.B.A.CEO

Founder, President, Chief Executive Officer, Secretary & Director

Todd Horich M.B.A., Ph.D.

Senior Vice President of Marketing, Commercial Operations & Market Access

Jeff Bozick

Senior Vice President of Supply Chain

Jonathan Rubin M.B.A., M.D.

Senior Vice President of Research & Development and Chief Medical Officer

Bryan A. Roecklein Ph.D.

Senior Vice President of Corporate Development

Total 8 executives

SUPN Frequently asked questions

What is Supernus Pharmaceuticals, Inc. (SUPN) Stock Price?

Current stock price of Supernus Pharmaceuticals, Inc. (SUPN) stock is $44.030. The stock price is +0.66% higher in the session. The intraday range can be seen from this page. Volume of Supernus Pharmaceuticals, Inc. (SUPN) stock is 445.94K.

Last updated at 02 Sept 2026, 08:00 pm.

Why is the Supernus Pharmaceuticals, Inc. (SUPN) stock price going up or down today?

The stock price of Supernus Pharmaceuticals, Inc. (SUPN) can change with earnings, company news, and overall market sentiment. Supernus Pharmaceuticals, Inc. operates in the Healthcare / Drug Manufacturers - Specialty & Generic market, so sector-wide moves can also affect the share price. Use the live price, percentage change, and volume on this page to judge whether a move looks meaningful.

Is the Supernus Pharmaceuticals, Inc. stock expensive at its current price?

Whether Supernus Pharmaceuticals, Inc. looks expensive depends on valuation metrics versus its growth outlook. The P/E ratio shown for SUPN on this page is 14.39. EPS on this page is 3.06. Compare those figures with peers and growth expectations before deciding if the current Supernus Pharmaceuticals, Inc. price is justified.

How has the stock price of Supernus Pharmaceuticals, Inc. (SUPN) performed historically?

Historical performance for Supernus Pharmaceuticals, Inc. (SUPN) is shown on the price chart on this page. Review multi-period moves alongside volume to see how SUPN reacted to past earnings and market events.

Should I buy Supernus Pharmaceuticals, Inc. (SUPN) stock, at this price?

Buying Supernus Pharmaceuticals, Inc. (SUPN) depends on your risk tolerance, time horizon, and portfolio needs. As a Healthcare name, weigh the live quote, key stats, and valuation links on this page rather than a single price point.